Relapse prevention in panic disorder with pharmacotherapy: where are we now?

References

• Kessler RC, Petukhova M, Sampson NA, et al. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169–184.
   PubMed Web of Science ®Google Scholar
• de Jonge P, Roest AM, Lim CCW, et al. Cross-national epidemiology of panic disorder and panic attacks in the world mental health surveys. Depress Anxiety. 2016;33(12):1155–1177.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
   Google Scholar
• Bystritsky A, Kerwin L, Niv N, et al. Clinical and subthreshold panic disorder. Depress Anxiety [Internet]. 2010;27(4):381–389. Available from.
   PubMed Web of Science ®Google Scholar
• Brettschneider C, Bleibler F, Hiller TS, et al. The allocation of resources in the care for patients with panic disorder in Germany: an excess cost analysis informing policy and science. Cost Eff Resour Alloc [Internet]. 2019;17(1):9. Available from. https://pubmed.ncbi.nlm.nih.gov/31061640.
   PubMedGoogle Scholar
• Ophuis RH, Lokkerbol J, Hiligsmann M, et al. Early intervention for subthreshold panic disorder in the Netherlands: A model-based economic evaluation from a societal perspective. Chatterton M Lou, editor. PLoS One. 2018;13(2):e0193338.
   PubMed Web of Science ®Google Scholar
• Skapinakis P, Lewis G, Davies S, et al. Panic disorder and subthreshold panic in the UK general population: epidemiology, comorbidity and functional limitation. Eur Psychiatry [Internet]. 2011;26(6):354–362.
   PubMed Web of Science ®Google Scholar
• Batelaan N, Smit F, de Graaf R, et al. Economic costs of full-blown and subthreshold panic disorder. J Affect Disord [Internet]. 2007;104(1–3):127–136.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder, second edition. 90. 2009. [cited 2020 Jun 1]. Available from: http://www.psychiatryonline.com/pracGuide/pracGuideTopic_9.aspx.
   Google Scholar
• National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: management [Internet]. NICE; 2011. [cited 2020 Jun 1]. Available from https://www.nice.org.uk/guidance/cg113
   Google Scholar
• Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93–106.
   PubMed Web of Science ®Google Scholar
• Perna G, Caldirola D. Management of treatment-resistant panic disorder. Curr Treat Options Psychiatry [Internet]. 2017;4(4):371–386. [cited 2017 Oct 24]. Available from: https://pubmed.ncbi.nlm.nih.gov/29238651
   PubMedGoogle Scholar
• Perna G, Alciati A, Riva A, et al. Long-term pharmacological treatments of anxiety disorders: an updated systematic review. Curr Psychiatry Rep [Internet]. 2016;18(3):23.
   PubMed Web of Science ®Google Scholar
• Batelaan NM, Van Balkom AJLM, Stein DJ. Evidence-based pharmacotherapy of panic disorder: an update. Available from Int J Neuropsychopharmacol [Internet]. 2012;15(3):403–415.
   PubMed Web of Science ®Google Scholar
• Andersch S, Hetta J. A 15-year follow-up study of patients with panic disorder. Available from Eur Psychiatry [Internet]. 2003;18(8):401–408.
   PubMed Web of Science ®Google Scholar
• Toni C, Perugi G, Frare F, et al. A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants. Pharmacopsychiatry [Internet]. 2000;33(4):121–131.
   PubMed Web of Science ®Google Scholar
• Choy Y, Peselow ED, Case BG, et al. Three-year medication prophylaxis in panic disorder: to continue or discontinue? A naturalistic study. Compr Psychiatry [Internet]. 2007;48(5):419–425.
   PubMed Web of Science ®Google Scholar
• Freire RC, Amrein R, Mochcovitch MD, et al. A 6-year posttreatment follow-up of panic disorder patients. J Clin Psychopharmacol [Internet]. 2017;37(4):429–434.
   PubMed Web of Science ®Google Scholar
• Batelaan NM, Bosman RC, Muntingh A, et al. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. 2017;358:j3927.
   PubMedGoogle Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol [Internet]. 2009;62(10):e1–e34.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: Amer Psychiatric Pub; 1980.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd text rev.. Amer Psychiatric Pub, editor. Washington, DC: Amer Psychiatric Pub;1987.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th. Amer Psychiatric Pub, editor. Washington, DC: Amer Psychiatric Pub;1994.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th. text rev. Pub AP, editor Amer Psychiatric Pub;2000.
   Google Scholar
• Centers for Disease Control and Prevention. International classification of diseases, ninth revision (ICD-9). 1987.
   Google Scholar
• Centers for Disease Control and Prevention. International classification of diseases, ninth revision, clinical modification (ICD-9-CM). 1979.
   Google Scholar
• Centers for Disease Control and Prevention. International classification of diseases, tenth revision (ICD-10). 1994.
   Google Scholar
• Michelson D, Pollack M, Lydiard RB, et al. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. Br J Psychiatry [Internet]. 1999;174(3):213–218.
   PubMedGoogle Scholar
• Michelson D, Lydiard RB, Pollack MH, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry [Internet]. 1998;155(11):1570–1577.
   PubMed Web of Science ®Google Scholar
• Mavissakalian MR, Perel JM. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry [Internet]. 1999;56(9):821.
   PubMed Web of Science ®Google Scholar
• Mavissakalian M, Perel J, Talbott-Green M, et al. Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. Biol Psychiatry. 1998;43(11):848–854.
   PubMed Web of Science ®Google Scholar
• Mavissakalian M, Perel J. 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia. Ann Clin Psychiatry [Internet]. 2001;132:63–67.
   PubMedGoogle Scholar
• Mavissakalian MR, Perel JM. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J Clin Psychopharmacol [Internet]. 2002;22(3):294–299.
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Wolkow R, Rubin A, et al. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand [Internet]. 2008;104(4):289–298.
   Google Scholar
• Kamijima K, Kuboki T, Kumano H, et al. A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. Int Clin Psychopharmacol [Internet]. 2005;20(5):265–273.
   PubMed Web of Science ®Google Scholar
• Ferguson JM, Khan A, Mangano R, et al. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry [Internet]. 2007;68(1):58–68.
   PubMed Web of Science ®Google Scholar
• Perna G, Schruers K, Alciati A, et al. Novel investigational therapeutics for panic disorder. Expert Opin Investig Drugs. 2015;24(4):491–505. Informa Healthcare.
   PubMed Web of Science ®Google Scholar
• Caldirola D, Alciati A, Riva A, et al. Are there advances in pharmacotherapy for panic disorder? A systematic review of the past five years. Expert Opin Pharmacother. 2018;19(12):1357–1368. Taylor and Francis Ltd. .
   PubMed Web of Science ®Google Scholar
• Caldirola D, Perna G, Toward a personalized therapy for panic disorder: preliminary considerations from a work in progress. Neuropsychiatr Dis Treat [Internet]. 2019;15:1957–1970. Available from https://www.dovepress.com/toward-a-personalized-therapy-for-panic-disorder-preliminary-considera-peer-reviewed-article-NDT.
   PubMed Web of Science ®Google Scholar
• Dannon PN, Iancu I, Cohen A, et al. Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry [Internet]. 2004;4(1):16. Available from.
   PubMedGoogle Scholar
• Mavissakalian M, Perel JM. Protective effects of imipramine maintenance in panic disorder with agoraphobia. Eur Neuropsychopharmacol [Internet]. 1992;2(3):380.
   Google Scholar
• Lotufo-Neto F, Bernik M, Ramos RT, et al. A dose-finding and discontinuation study of clomipramine in panic disorder. J Psychopharmacol [Internet]. 2001;15(1):13–17.
   PubMed Web of Science ®Google Scholar
• Mavissakalian MR, Guo S. Early detection of relapse in panic disorder. Available from Acta Psychiatr Scand [Internet]. 2004;110(5):393–399.
   PubMed Web of Science ®Google Scholar
• Lepola UM, Wade AG, Leinonen EV, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry [Internet]. 1998;59(10):528–534.
   PubMed Web of Science ®Google Scholar
• Lydiard RB, Steiner M, Burnham D, et al. Efficacy studies of paroxetine in panic disorder. Psychopharmacol Bull [Internet]. 1998;34:175–182. Available from http://www.ncbi.nlm.nih.gov/pubmed/9640997
   PubMedGoogle Scholar
• Simon NM, Safren SA, Otto MW, et al. Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder. J Affect Disord [Internet]. 2002;69(1–3):201–208.
   PubMed Web of Science ®Google Scholar
• Pané-Farré CA, Fenske K, Stender JP, et al. Sub-threshold panic attacks and agoraphobic avoidance increase comorbidity of mental disorders: results from an adult general population sample. J Anxiety Disord [Internet]. 2013;27(5):485–493.
   PubMed Web of Science ®Google Scholar
• Oral E, Aydin N, Gulec M, et al. Panic disorder and subthreshold panic in the light of comorbidity: a follow-up study. Compr Psychiatry [Internet]. 2012;53(7):988–994.
   PubMed Web of Science ®Google Scholar
• Meuret AE, Kroll J, Ritz T. Panic disorder comorbidity with medical conditions and treatment implications. Annu Rev Clin Psychol [Internet]. 2017;13(1):209–240.
   PubMedGoogle Scholar
• Latas M, Vučinić Latas D, Spasić Stojaković M. Anxiety disorders and medical illness comorbidity and treatment implications. Curr Opin Psychiatry [Internet]. 2019;32(5):429–434.
   PubMed Web of Science ®Google Scholar
• Meuret AE, Tunnell N, Roque A. Anxiety disorders and medical comorbidity: treatment implications [Internet]. Adv Exp Med Biol. 2020;237–261. Springer Singapore. 10.1007/978-981-32-9705-0_15
   PubMed Web of Science ®Google Scholar
• Caldirola D, Schruers KR, Nardi AE, et al. Is there cardiac risk in panic disorder? An updated systematic review. J Affect Disord [Internet]. 2016;194:38–49.
   PubMed Web of Science ®Google Scholar
• Perna G, Caldirola D, Is panic disorder a disorder of physical fitness? A heuristic proposal. F1000Research [Internet]. 2018;7:294. Available from https://pubmed.ncbi.nlm.nih.gov/29623195.
   PubMedGoogle Scholar
• Davidoff J, Christensen S, Khalili DN, et al. Quality of life in panic disorder: looking beyond symptom remission. Qual Life Res [Internet]. 2011;21(6):945–959.
   PubMed Web of Science ®Google Scholar
• Perna G, Grassi M, Caldirola D, et al. The revolution of personalized psychiatry: will technology make it happen sooner? Psychol Med. 2018;48(5):705–713. .
   PubMed Web of Science ®Google Scholar
• Meuret AE, Rosenfield D, Wilhelm FH, et al. Do unexpected panic attacks occur spontaneously? Biol Psychiatry. 2011;70(10):985–991. [cited 2011 Jul 23]. Available from: https://pubmed.ncbi.nlm.nih.gov/21783179
   PubMed Web of Science ®Google Scholar
• Perna G, Alciati A, Daccò S, et al. Personalized psychiatry and depression: the role of sociodemographic and clinical variables. Psychiatry Investig [Internet]. 2020;17(3):193–206.
   PubMed Web of Science ®Google Scholar